At a glance
- Originator Nihon Schering
- Class Antipsychotics
- Mechanism of Action Sigma-1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Schizophrenia
Most Recent Events
- 27 Mar 2000 Mitsui Pharmaceuticals has been acquired by Schering AG
- 18 Aug 1999 Preclinical development for Schizophrenia in Japan (PO)